Investigational drug · Phase 3
Elenestinib
Also called: BLU-263
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "Elenestinib"
First trial start
2021
Nov 30, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Elenestinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Indolent Systemic Mastocytosis
- Smoldering Systemic Mastocytosis
Largest trials
Live from ClinicalTrials.gov: studies naming "Elenestinib" as an intervention, largest first.
- (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic MastocytosisPivotal-lookingRecruiting
Blueprint Medicines CorporationIndustry
NCT04910685 · 534 participants (planned) · Start Nov 30, 2021 · Primary completion Sep 30, 2032
Drug: Elenestinib; Placebo · For: Indolent Systemic Mastocytosis; Smoldering Systemic Mastocytosis
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 88 sites in all
Blueprint Medicines CorporationIndustry
NCT07388511 · 20 participants · Start Feb 5, 2026 · Primary completion Apr 2, 2026
Drug: Elenestinib; Midazolam and 1 more · For: Healthy Participants
Sites: Tempe, Arizona
Blueprint Medicines CorporationIndustry
NCT05609942 · 9 participants · Start Sep 25, 2023 · Primary completion Jan 14, 2025
Drug: BLU-263; Azacitidine · For: Advanced Systemic Mastocytosis
Sites: Palo Alto, California; Boston, Massachusetts; Ann Arbor, Michigan · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Targeted KIT inhibitors: paradigm shift in the treatment of systemic mastocytosis.
Abbas HA, Chifotides HT, Bose P · Expert Opin Investig Drugs 2026
- Tyrosine Kinase Inhibitors for the Treatment of Mast Cell Diseases: Review and Update.
Carpio-Escalona LV, Prieto-García A, Morales-Cabeza C, et al. · J Investig Allergol Clin Immunol 2025
- New treatments for systemic mastocytosis in 2025.
Costanzo G, Marzio V, Cavaglià E, et al. · Curr Opin Allergy Clin Immunol 2025
- SOHO State of the Art Update and Next Questions: Current and Emerging Therapies for Systemic Mastocytosis.
Chifotides HT, Bose P · Clin Lymphoma Myeloma Leuk 2025
- Systemic Mastocytosis: State of the Art.
Farmer I, Radia DH · Curr Hematol Malig Rep 2024
- Management of Advanced Systemic Mastocytosis: Clinical Challenges.
Tremblay D, Wagner NE, Mascarenhas J · J Blood Med 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.